CAR-T FOR DLBCL IN CHINA:
ELIGIBILITY, OUTCOMES & ACCESS
Relapsed/refractory DLBCL has a poor prognosis with conventional salvage — CAR-T therapy has fundamentally changed what is achievable, and China's approved products make this accessible at a fraction of Western costs.
analyticsAt a Glance
- check_circleCAR-T produces 40–60% complete remission rates in 3L+ DLBCL — with ~40% of CRs remaining durable at 4 years
- check_circleChina has approved relma-cel, axicabtagene (Yescarta), and lisocabtagene (Breyanzi) for DLBCL
- check_circleStandard eligibility: relapsed or refractory DLBCL after ≥2 prior lines including rituximab and anthracycline
- check_circleCancerFax coordinates the complete DLBCL CAR-T access pathway in China — from eligibility to discharge
Why CAR-T Has Changed DLBCL Treatment
Diffuse large B-cell lymphoma (DLBCL) — the most common aggressive non-Hodgkin lymphoma — has historically carried a poor prognosis in the relapsed/refractory setting. Before CAR-T, the complete response rate to salvage chemotherapy followed by autologous stem cell transplant (ASCT) was approximately 20–25% in patients who progressed after first-line R-CHOP. CD19-directed CAR-T therapy produces CR rates of 40–60% in this population — and a subset of these remissions are durable, representing a form of potential cure.
“For patients with DLBCL that has relapsed after standard treatment, CAR-T is not an experimental option — it is the most effective therapy available.”
DLBCL: The Standard-of-Care Context
First-line DLBCL treatment is R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) — achieving cure in ~60% of patients. The remaining ~40% relapse or are refractory. Second-line salvage chemotherapy followed by ASCT rescues approximately 20% of these patients. For those who fail ASCT or are ineligible — CAR-T is now standard third-line therapy in most international guidelines.
Why CD19 Is the Right Target for DLBCL
DLBCL is a B-cell malignancy — and essentially all DLBCL expresses CD19 at diagnosis. CD19 is not lost at the same frequency in lymphoma as in ALL — making it a more stable target. The main resistance mechanism in DLBCL CAR-T failure is not antigen loss but T cell exhaustion, poor in vivo expansion, and immunosuppressive tumour microenvironment.
DLBCL CAR-T Efficacy: Key Numbers from Pivotal Trials
Response rate benchmarks from the major pivotal trials supporting CD19 CAR-T approvals in DLBCL — the data that defines current expectations.
- 52%Complete response rate — axi-cel in 3L+ DLBCL (ZUMA-1, 2-year follow-up)The ZUMA-1 pivotal trial of axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma demonstrated 52% CR at 2 years, with ~40% of patients remaining in ongoing remission at 4+ years — establishing CAR-T's potential for durable response.
- 40%Complete response rate — tisagenlecleucel in 3L+ DLBCL (JULIET)The JULIET trial of tisagenlecleucel showed 40% CR at 3 months — with 65% of responders maintaining response at 12 months and 61% at 24 months. A different manufacturing approach (4-1BB costimulatory domain) produces longer T cell persistence than axi-cel's CD28 domain.
- 46%Complete response rate — liso-cel in 3L+ DLBCL (TRANSCEND)Lisocabtagene maraleucel (liso-cel) in TRANSCEND: 46% CR with a lower CRS and ICANS rate than axi-cel — approved for 3L+ DLBCL and for early relapsed DLBCL in combination with the TRANSFORM trial dataset.
DLBCL CAR-T Eligibility: Standard Criteria and Common Exclusions
Eligibility criteria for CD19-directed CAR-T in DLBCL are broadly consistent across Chinese and Western approved products — the main variables are prior treatment lines and organ function thresholds.
| Eligibility Factor | Standard Requirement | Notes |
|---|---|---|
| Diagnosis | Histologically confirmed DLBCL, PMBCL, TFL (DLBCL transformed from FL or CLL), HGBCL | Confirm by pathology with IHC; DLBCL NOS, GCB or non-GCB both eligible |
| CD19 expression | CD19+ confirmed on recent biopsy or bone marrow | CD19 expression should be confirmed from relapsed tissue where possible — not assumed from diagnosis |
| Prior treatment lines | ≥2 prior lines including rituximab-containing and anthracycline-containing regimen | Standard 3L threshold for relapsed disease; ZUMA-7 data supports 2L use in early relapsed/refractory (see separate page) |
| Performance status | ECOG 0–1 (some centres consider ECOG 2 with MDT discussion) | Higher PS is associated with higher CRS severity and lower response rate |
| Organ function | Adequate renal (Cr <1.5× ULN), hepatic (ALT/AST <5× ULN, bilirubin <2× ULN), cardiac (LVEF ≥45–50%), pulmonary (SpO₂ ≥92% on room air) | These thresholds enable tolerance of lymphodepletion and management of potential CRS |
| Active CNS lymphoma involvement | Variable — many protocols exclude active parenchymal CNS DLBCL | Leptomeningeal involvement typically exclusionary; some centres include patients with treated stable CNS disease |
| Prior allogeneic transplant | Typically excluded or requires ≥6 months from allo-SCT, no active GvHD, off immunosuppression | Allogeneic CAR-T products require separate consideration for allo-SCT recipients |
DLBCL CAR-T Outcomes: China Published Data vs Global Pivotal Trials
Published real-world and trial data from Chinese CAR-T centres demonstrates outcomes broadly consistent with global pivotal trial benchmarks.
Complete Response Rates in 3L+ DLBCL
Sources: ZUMA-1 (axi-cel), JULIET (tisa-cel), TRANSCEND (liso-cel), Chinese real-world registry data (NCCN China centres). All data from ≥3 prior lines unless otherwise noted.
- Axi-cel — ZUMA-1 (global)52% CR
- Liso-cel — TRANSCEND (global)46% CR
- Tisa-cel — JULIET (global)40% CR
- Relma-cel — Chinese real-world series44–50% CR
- Axi-cel — Chinese academic centres48–54% CR
Preparing for DLBCL CAR-T: Bridging Therapy and Pre-Infusion Considerations
The 3–5 week manufacturing period between leukapheresis and infusion requires careful disease management — particularly for patients with rapidly progressing DLBCL.
- 1
Bridging Therapy Selection
Bridging therapy controls disease during manufacturing without compromising CAR-T expansion. Preferred agents: polatuzumab + bendamustine + rituximab; gemcitabine-based regimens; ibrutinib for Richter transformation; radiotherapy for focal bulky disease. Avoid prolonged high-dose steroid bridging — impairs T cell function.
- 2
Response Assessment Before Conditioning
PET-CT or CT scan is performed before starting lymphodepletion to confirm disease status and extent. Massive tumour bulk (SUV >10, multiple large lesions) at the time of infusion is a predictor of higher CRS risk and lower response rate — additional bridging may be indicated.
- 3
Lymphodepletion Chemotherapy
Standard lymphodepletion: fludarabine 25–30 mg/m² + cyclophosphamide 300–500 mg/m² daily for 3 days, completed 2 days before CAR-T infusion. Creates immune 'space' for CAR-T expansion and eliminates regulatory T cells that suppress the infused product.
- 4
CRS and ICANS Risk Stratification
High disease burden at infusion and high inflammatory markers (ferritin, CRP, IL-6) predict higher CRS risk. The treating haematologist should discuss individual CRS/ICANS risk before infusion — higher-risk patients need more intensive monitoring and earlier tocilizumab prophylaxis consideration.
- 5
Response Assessment at 1 and 3 Months Post-Infusion
PET-CT at 1 month and 3 months post-infusion defines treatment response. Complete metabolic response (CMR) at 3 months is the primary endpoint and strongly predicts durability. Partial responders and stable disease patients require continued monitoring and may need consolidation.
Frequently Asked Questions
Common questions from DLBCL patients considering CAR-T therapy in China.
About DLBCL CAR-T in China
I have relapsed DLBCL — am I too old for CAR-T?
Age is not an absolute contraindication for CAR-T in DLBCL. Patients over 70 have received CAR-T in clinical trials and real-world series with acceptable toxicity — the key predictors of tolerability are performance status and organ function, not chronological age. Fit patients in their 70s with good organ function and ECOG 0–1 are routinely offered CAR-T at high-volume centres. Chinese CAR-T centres will assess individual fitness rather than applying an age cutoff.
Does it matter whether my DLBCL is GCB or non-GCB subtype?
Historically, non-GCB (activated B-cell, ABC-DLBCL) has had worse outcomes with salvage chemotherapy. Early CAR-T data suggested similar response rates across GCB and non-GCB subtypes — both are eligible for CD19 CAR-T regardless of cell-of-origin. However, double-hit/triple-hit DLBCL (MYC + BCL2 and/or BCL6 rearrangement) may have a slightly lower durable response rate with CAR-T, though it remains the most effective salvage option available.
What if I relapse after CAR-T — what are the next options?
Relapse after CD19-directed CAR-T in DLBCL is challenging. Options depend on whether CD19 expression is maintained: CD19-positive relapse may respond to a different CD19 CAR-T construct or to polatuzumab + bendamustine + rituximab; CD19-negative relapse requires non-CD19-targeted approaches including bispecific antibodies (mosunetuzumab, epcoritamab), loncastuximab, or CD22-directed CAR-T (available in Chinese trials). CancerFax can assess options at relapse.
How do I prepare emotionally and practically for CAR-T in China?
CancerFax provides patients and families with a pre-travel preparation guide covering: what to bring to China, what to expect during the hospital stay, how to communicate with family back home, managing childcare or work obligations during the 4–6 week stay, and financial preparation. A dedicated CancerFax coordinator accompanies each patient throughout the process — ensuring no practical question goes unanswered.
More from the CAR-T Cell Therapy Resource Library
Continue exploring CAR-T guides — from target biology to second-line use and ALL.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Check Your DLBCL CAR-T Eligibility Through CancerFax
CancerFax reviews your DLBCL pathology, CD19 expression, prior treatment lines, and performance status to assess eligibility for Chinese-approved CAR-T products — and manages the full access process for eligible patients.
This content is for informational purposes only. CAR-T eligibility must be formally assessed by a qualified haematologist at an accredited CAR-T centre.